ArticleFrontiers in nutrition2025
Biochanin A enhances type H vessel formation and improves epiphysis deformities following ischemic osteonecrosis in juvenile mouse.
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting type H vessels with bioactive metabolites from traditional Chinese botanical drugs: a therapeutic strategy for skeletal disorders.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Legg-Calvé-Perthes disease (LCPD) ranks as one of the most severe hip conditions that can lead to permanent deformity of the femoral head in children. Despite its severity, no effective pharmacological treatments are currently available, highlighting the urgent need for novel therapeutic agents. And platelet-derived growth factor-BB (PDGF-BB), a vital biological macromolecule, plays a critical role in vascular remodeling and bone regeneration, thereby establishing itself as a crucial drug target for activating bone repair. In this study, we demonstrate that biochanin A (BCA), a soybean-derived isoflavone, significantly prevents epiphyseal collapse and promotes bone regeneration in a juvenile ischemic osteonecrosis (JIO) model. Mechanistically, BCA enhances the formation of type H vessels in bone by indirectly facilitating the interaction between osteoclast precursors and endothelial cells, thereby accelerating bone repair in JIO. Specifically, BCA suppresses the differentiation of mature osteoclasts, expands the population of osteoclast precursors, and stimulates the secretion of PDGF-BB, which in turn promotes type H vessels angiogenesis. Our findings highlight the potential of BCA as a promising therapeutic candidate for the treatment of LCPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.